TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates

Company Performance - TransMedics reported quarterly earnings of $0.92 per share, exceeding the Zacks Consensus Estimate of $0.48 per share, and up from $0.35 per share a year ago, representing an earnings surprise of +91.67% [1] - The company posted revenues of $157.37 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.79%, compared to $114.31 million in the same quarter last year [2] - Over the last four quarters, TransMedics has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - TransMedics shares have increased approximately 68.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $139.52 million, and for the current fiscal year, it is $1.89 on revenues of $580.37 million [7] Industry Outlook - The Medical - Instruments industry, to which TransMedics belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of TransMedics' stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]